Disc Medicine (IRON) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
The meeting was called to order by the Executive Chairman, with directors and key executives recognized in attendance.
The agenda included formal business as described in the notice and proxy statement sent to stockholders.
Representatives from the audit firm and outside counsel were present.
Corporate governance
Quorum was established with over 35.9 million shares represented out of 38.2 million entitled to vote.
Voting procedures were explained, and polls were opened for stockholder participation.
Only stockholders with valid credentials could vote and ask questions.
Board and executive committee updates
Three nominees were presented for election as Class III directors for a three-year term, with no alternative nominations received.
The board unanimously recommended the election of the nominated directors.
Latest events from Disc Medicine
- DISC-0974 shows 40%-80% response rates in myelofibrosis anemia, addressing a major unmet need.IRON
Status Update16 Jul 2026 - Lead asset nears NDA filing as pipeline advances and commercial launch preparations accelerate.IRON
H.C. Wainwright 27th Annual Global Investment Conference8 Jul 2026 - Advancing late-stage hematology pipeline with strong data, robust funding, and near-term commercialization.IRON
Barclays 27th Annual Global Healthcare Conference8 Jul 2026 - Accelerated FDA review and robust clinical data drive pipeline and funding through 2029.IRON
Status Update8 Jul 2026 - Bitopertin and selcodebart show strong, durable efficacy, with pivotal data expected in Q4 2026.IRON
Study update15 Jun 2026 - Pivotal data and regulatory milestones for key anemia programs are expected by year-end.IRON
Jefferies Global Healthcare Conference 20263 Jun 2026 - Late-stage pipeline targets EPP, MF anemia, and PV with pivotal data expected by 2027.IRON
Corporate presentation3 Jun 2026 - APOLLO study enrollment exceeded targets, signaling high demand and unmet need for EPP therapies.IRON
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Net loss widened to $63.5M as bitopertin's FDA review was delayed; cash runway extends to 2029.IRON
Q1 20265 May 2026